TETRAHYDRODEOXYCORTICOSTERONE CAS: 567-03-3

CAS NO: 567-03-3
TETRAHYDRODEOXYCORTICOSTERONE
Chemical Name: TETRAHYDRODEOXYCORTICOSTERONE
Molecular Formula: C21H34O3
Formula Weight: 334.49
CAS No.: 567-03-3
Description Review
Description

Tetrahydrodeoxycorticosterone (THDOC), also known as 3-alpha, 21-dihydroxy-5-beta-pregnane-20-one or 3-alpha, 21-dihydroxy-5-beta-pregnan-20-one, is a neurosteroid hormone that is produced in the adrenal gland. It is a metabolite of deoxycorticosterone (DOC) and is involved in the regulation of the stress response and other physiological processes. In this article, we will explore the molecular details of THDOC, its potential benefits, mechanism, safety, and side effects.

Chemical Name:

3-alpha, 21-dihydroxy-5-beta-pregnane-20-one or 3-alpha, 21-dihydroxy-5-beta-pregnan-20-one

Molecular Formula:

C21H34O3

Formula Weight:

334.49 g/mol

CAS No:

567-03-3

Top Ten Keywords and Synonyms:

  1. Tetrahydrodeoxycorticosterone
  2. THDOC
  3. Neurosteroid hormone
  4. Adrenal gland
  5. Stress response
  6. Molecular formula C21H34O3
  7. CAS number 567-03-3
  8. 5-alpha-pregnan-3-beta-ol-20-one
  9. Deoxycorticosterone metabolite
  10. GABA-A receptor modulator

Health Benefits of THDOC:

THDOC has been shown to have a variety of effects on physiological processes, including modulating the activity of the GABA-A receptor, which is involved in the regulation of anxiety and stress. It has also been shown to have anti-inflammatory effects in the brain, which could be useful in the treatment of neurodegenerative diseases such as Alzheimer's and Parkinson's disease.

Potential Effects of THDOC:

THDOC has been shown to modulate the activity of the GABA-A receptor, which is involved in the regulation of anxiety and stress. It has also been shown to have neuroprotective effects, potentially due to its anti-inflammatory properties in the brain. THDOC has also been shown to modulate the activity of several neurotransmitter systems, including dopamine, norepinephrine, and serotonin, which could have implications for the treatment of various psychiatric disorders.

Product Mechanism:

THDOC acts as a positive allosteric modulator of the GABA-A receptor, which enhances the activity of this receptor and increases the inhibitory tone in the brain. This can lead to the reduction of anxiety and stress-related behaviors. Additionally, THDOC has been shown to modulate the activity of several neurotransmitter systems, including dopamine, norepinephrine, and serotonin, which could have implications for the treatment of various psychiatric disorders.

Safety:

THDOC appears to be generally safe, although more research is needed to fully establish its safety profile. It is a natural metabolite of deoxycorticosterone and is produced in the body under normal conditions. However, because it can modulate the activity of the GABA-A receptor, there may be potential for interactions with other medications or substances that affect this receptor.

Side Effects:

THDOC is generally well-tolerated by the body and does not appear to have significant side effects. However, because it can modulate the activity of the GABA-A receptor, there may be potential for interactions with other medications or substances that affect this receptor.

Dosing Information:

As THDOC is a natural metabolite of deoxycorticosterone, there is no standard dosing regimen for this compound. However, it can be administered exogenously in research studies to investigate its effects on various physiological processes. The appropriate dosing regimen would depend on the specific research question and the desired endpoint.

Conclusion:

Tetrahydrodeoxycorticosterone is a naturally occurring neurosteroid hormone that is involved in the regulation of the stress response and other physiological processes. Its ability to modulate the activity of the GABA-A receptor, as well as its anti-inflammatory effects in the brain, suggest that it may have potential applications in the treatment of anxiety, stress-related disorders, and neurodegenerative diseases. While THDOC appears to be generally safe and well-tolerated by the body, more research is needed to fully establish its safety and efficacy profile, and to determine the optimal dosing and administration regimens for this compound.

Review
Review

ver_code
1/3
X
Send your message to us
please select your country
  • Afghanistan
  • Aland Islands
  • Albania
  • Algeria
  • American Samoa
  • Andorra
  • Angola
  • Anguilla
  • Antigua and Barbuda
  • Argentina
  • Armenia
  • Aruba
  • Australia
  • Austria
  • Azerbaijan
  • Bahamas
  • Bahrain
  • Bangladesh
  • Barbados
  • Belarus
  • Belgium
  • Belize
  • Benin
  • Bermuda
  • Bhutan
  • Bolivia
  • Bosnia and Herzegovina
  • Botswana
  • Bouvet Island
  • Brazil
  • British Indian Ocean Territory
  • British Virgin Islands
  • Brunei Darussalam
  • Bulgaria
  • Burkina Faso
  • Burundi
  • Cambodia
  • Cameroon
  • Canada
  • Cape Verde
  • Caribbean Netherlands
  • Cayman Islands
  • Central African Republic
  • Chad
  • Chile
  • China
  • Christmas Island
  • Cocos Islands
  • Colombia
  • Comoros
  • Congo
  • Cook Islands
  • Costa Rica
  • Cote D'ivoire
  • Cuba
  • Curaçao
  • Cyprus
  • Czech Republic
  • Democratic People's Republic of Korea
  • Democratic Republic of the Congo
  • Denmark
  • Djibouti
  • Dominica
  • East Timor
  • Ecuador
  • Egypt
  • El Salvador
  • Equatorial Guinea
  • Eritrea
  • Estonia
  • Ethiopia
  • Falkland Islands
  • Faroe Islands
  • Fiji
  • Finland
  • France
  • French Guiana
  • French Polynesia
  • French Southern Territories
  • Gabon
  • Gambia
  • Georgia
  • Germany
  • Ghana
  • Gibraltar
  • Greece
  • Greenland
  • Grenada
  • Guadeloupe
  • Guam
  • Guatemala
  • Guernsey
  • Guinea
  • Guinea-Bissau
  • Guyana
  • Haiti
  • Heard Island and Mcdonald Islands
  • Honduras
  • Hong Kong, China
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Iran
  • Iraq
  • Ireland
  • Isle of Man
  • Israel
  • Italy
  • Jamaica
  • Japan
  • Jordan
  • Kazakhstan
  • Kenya
  • Kiribati
  • Korea
  • Kosovo
  • Kuwait
  • Kyrgyzstan
  • Laos
  • Latvia
  • Lebanon
  • Lesotho
  • Liberia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Macau, China
  • Macedonia
  • Madagascar
  • Malawi
  • Malaysia
  • Maldives
  • Mali
  • Malta
  • Marshall Islands
  • Martinique
  • Mauritania
  • Mauritius
  • Mayotte
  • Mexico
  • Micronesia
  • Moldova
  • Monaco
  • Mongolia
  • Montenegro
  • Montserrat
  • Morocco
  • Mozambique
  • Myanmar
  • Namibia
  • Nauru
  • Nepal
  • Netherlands
  • Netherlands Antilles
  • New Caledonia
  • New Zealand
  • Nicaragua
  • Niger
  • Nigeria
  • Niue
  • Norfolk Island
  • Northern Mariana Islands
  • Norway
  • Oman
  • Pakistan
  • Palau
  • Palestine
  • Panama
  • Papua New Guinea
  • Paraguay
  • Peru
  • Philippines
  • Pitcairn Islands
  • Poland
  • Portugal
  • Puerto Rico
  • Qatar
  • Reunion
  • Romania
  • Russia
  • Rwanda
  • Saint Barthélemy
  • Saint Helena
  • Saint Kitts and Nevis
  • Saint Lucia
  • Saint Martin
  • Saint Pierre and Miquelon
  • Saint Vincent and the Grenadines
  • San Marino
  • Sao Tome and Principe
  • Saudi Arabia
  • Senegal
  • Serbia
  • Seychelles
  • Sierra Leone
  • Singapore
  • Sint Maarten
  • Slovakia
  • Slovenia
  • Solomon Islands
  • Somalia
  • South Africa
  • South Georgia and The South Sandwich Islands
  • Spain
  • Sri Lanka
  • State of Libya
  • Sudan
  • Suriname
  • Svalbard and Jan Mayen
  • Swaziland
  • Sweden
  • Switzerland
  • Syrian Arab Republic
  • TaiWan, China
  • Tajikistan
  • Tanzania
  • Thailand
  • The Republic of Croatia
  • Togo
  • Tokelau
  • Tonga
  • Trinidad and Tobago
  • Tunisia
  • Turkey
  • Turkmenistan
  • Turks and Caicos Islands
  • Tuvalu
  • Uganda
  • Ukraine
  • United Arab Emirates
  • United Kingdom
  • United States
  • United States Minor Outlying Islands
  • Uruguay
  • US Virgin Islands
  • Uzbekistan
  • Vanuatu
  • Vatican City State
  • Venezuela
  • Vietnam
  • Wallis and Futuna Islands
  • Western Sahara
  • Western Samoa
  • Yemen
  • Zambia
  • Zimbabwe
ver_code